Clinical Trials Browser

Phase 1/2 × atezolizumab × Myeloid × Clear all

NCT02935361 2026-01-29

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Phase 1/2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic